Choose Your Location:

Contact us

Press Releases

The following UK & Ireland Press Releases contain information that is intended for journalists only.
For media enquiries about our press releases please contact mediaenquiries.UK-IE@ipsen.com.

CRSC-GB-000178

October 2024


8 results

NICE recommends Ipsen’s IQIRVO® (elafibranor) – the first me...
22 October 2024

Elafibranor is indicated for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in…

See more

U.K. MHRA grants marketing authorisation for Ipsen’s Iqirvo®...
08 October 2024

Elafibranor is indicated for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in…

See more

Ipsen appoints Ioana Parsons as General Manager, U.K. & ...
07 March 2024

LONDON, U.K., 6 March 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment…

See more

Ipsen Wrexham investment unveiled as Wrexham mayor joins 50t...
15 June 2023

WREXHAM, UK, 13 June 2023 – Ipsen today announced a £75 million investment in its…

See more

Ipsen’s response to NICE’s decision on Cabometyx® (cabozanti...
06 April 2023

SLOUGH, UK, 5th April 2023 – Ipsen is disappointed that the National Institute for Health…

See more

NICE recommends Cabometyx® (cabozantinib) for previously tre...
10 November 2022

Cabozantanib has been recommended by NICE as an option for treating advanced hepatocellular carcinoma (HCC),…

See more

Tánaiste joins Ipsen Ireland to launch upgraded manufacturin...
04 October 2022

Dublin, Ireland, 25th/26th September 2022 Tánaiste joins Ipsen Ireland to launch upgraded manufacturing site in…

See more

Ipsen announced overall Pharma Industry Company of the Year ...
30 June 2022

Ireland, May 2022 Blanchardstown-based, biopharmaceutical Ipsen has been announced overall Pharma Industry Company of the…

See more
© Ipsen Group 2024